BAJAJHCARE2026-07-012026-09-30BAJAJHCARE2026-09-30BAJAJHCARE2026-03-31BAJAJHCARE2026-04-012026-09-30BAJAJHCARE2026-07-012026-09-30in-capmkt:OtherExpenses1MemberBAJAJHCARE2026-07-012026-09-30in-capmkt:OtherExpenses2MemberBAJAJHCARE2026-07-012026-09-30in-capmkt:OtherExpenses3MemberBAJAJHCARE2026-07-012026-09-30in-capmkt:OtherExpenses4MemberBAJAJHCARE2026-07-012026-09-30in-capmkt:OtherExpenses5MemberBAJAJHCARE2026-07-012026-09-30in-capmkt:OtherExpenses6MemberBAJAJHCARE2026-07-012026-09-30in-capmkt:OtherExpenses7MemberBAJAJHCARE2026-07-012026-09-30in-capmkt:OtherExpenses8MemberBAJAJHCARE2026-07-012026-09-30in-capmkt:OtherExpenses9MemberBAJAJHCARE2026-07-012026-09-30in-capmkt:OtherExpenses10MemberBAJAJHCARE2026-04-012026-09-30in-capmkt:OtherExpenses1MemberBAJAJHCARE2026-04-012026-09-30in-capmkt:OtherExpenses2MemberBAJAJHCARE2026-04-012026-09-30in-capmkt:OtherExpenses3MemberBAJAJHCARE2026-04-012026-09-30in-capmkt:OtherExpenses4MemberBAJAJHCARE2026-04-012026-09-30in-capmkt:OtherExpenses5MemberBAJAJHCARE2026-04-012026-09-30in-capmkt:OtherExpenses6MemberBAJAJHCARE2026-04-012026-09-30in-capmkt:OtherExpenses7MemberBAJAJHCARE2026-04-012026-09-30in-capmkt:OtherExpenses8MemberBAJAJHCARE2026-04-012026-09-30in-capmkt:OtherExpenses9MemberBAJAJHCARE2026-04-012026-09-30in-capmkt:OtherExpenses10MemberBAJAJHCARE2026-09-30OtherNoncurrentFinancialAssetsDomain1BAJAJHCARE2026-09-30OtherNoncurrentFinancialAssetsDomain2BAJAJHCARE2026-09-30OtherNoncurrentAssetsDomain1BAJAJHCARE2026-09-30OtherNoncurrentAssetsDomain2BAJAJHCARE2026-09-30OtherNoncurrentAssetsDomain3BAJAJHCARE2026-09-30OtherCurrentFinancialAssetsDomain1BAJAJHCARE2026-09-30OtherCurrentFinancialAssetsDomain2BAJAJHCARE2026-09-30OtherCurrentFinancialAssetsDomain3BAJAJHCARE2026-09-30OtherCurrentFinancialAssetsDomain4BAJAJHCARE2026-09-30OtherCurrentFinancialAssetsDomain5BAJAJHCARE2026-09-30OtherCurrentAssetsDomain1BAJAJHCARE2026-09-30OtherCurrentAssetsDomain2BAJAJHCARE2026-09-30OtherCurrentAssetsDomain3BAJAJHCARE2026-09-30OtherCurrentAssetsDomain4BAJAJHCARE2026-09-30OtherNoncurrentFinancialLiabilitiesDomain1BAJAJHCARE2026-09-30OtherNoncurrentLiabilitiesDomain1BAJAJHCARE2026-09-30OtherCurrentFinancialLiabilitiesDomain1BAJAJHCARE2026-09-30OtherCurrentFinancialLiabilitiesDomain2BAJAJHCARE2026-09-30OtherCurrentFinancialLiabilitiesDomain3BAJAJHCARE2026-09-30OtherCurrentFinancialLiabilitiesDomain4BAJAJHCARE2026-09-30OtherCurrentLiabilitiesDomain1BAJAJHCARE2026-07-012026-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss1BAJAJHCARE2026-04-012026-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss1BAJAJHCARE2026-07-012026-09-30RelatedPartyTransactionDomain1BAJAJHCARE2026-06-30RelatedPartyTransactionDomain1BAJAJHCARE2026-09-30RelatedPartyTransactionDomain1BAJAJHCARE2026-07-012026-09-30RelatedPartyTransactionDomain2BAJAJHCARE2026-06-30RelatedPartyTransactionDomain2BAJAJHCARE2026-09-30RelatedPartyTransactionDomain2BAJAJHCARE2026-07-012026-09-30RelatedPartyTransactionDomain3BAJAJHCARE2026-06-30RelatedPartyTransactionDomain3BAJAJHCARE2026-09-30RelatedPartyTransactionDomain3BAJAJHCARE2026-07-012026-09-30RelatedPartyTransactionDomain4BAJAJHCARE2026-06-30RelatedPartyTransactionDomain4BAJAJHCARE2026-09-30RelatedPartyTransactionDomain4BAJAJHCARE2026-07-012026-09-30RelatedPartyTransactionDomain5BAJAJHCARE2026-06-30RelatedPartyTransactionDomain5BAJAJHCARE2026-09-30RelatedPartyTransactionDomain5BAJAJHCARE2026-07-012026-09-30RelatedPartyTransactionDomain6BAJAJHCARE2026-06-30RelatedPartyTransactionDomain6BAJAJHCARE2026-09-30RelatedPartyTransactionDomain6BAJAJHCARE2026-07-012026-09-30RelatedPartyTransactionDomain7BAJAJHCARE2026-06-30RelatedPartyTransactionDomain7BAJAJHCARE2026-09-30RelatedPartyTransactionDomain7BAJAJHCARE2026-07-012026-09-30RelatedPartyTransactionDomain8BAJAJHCARE2026-06-30RelatedPartyTransactionDomain8BAJAJHCARE2026-09-30RelatedPartyTransactionDomain8BAJAJHCARE2026-07-012026-09-30RelatedPartyTransactionDomain9BAJAJHCARE2026-06-30RelatedPartyTransactionDomain9BAJAJHCARE2026-09-30RelatedPartyTransactionDomain9BAJAJHCARE2026-07-012026-09-30RelatedPartyTransactionDomain10BAJAJHCARE2026-06-30RelatedPartyTransactionDomain10BAJAJHCARE2026-09-30RelatedPartyTransactionDomain10BAJAJHCARE2026-09-30Statement1BAJAJHCARE2026-07-012026-09-30Statement1BAJAJHCARE2026-09-30StatementDynamic1I1Statement1BAJAJHCARE2026-09-30StatementDynamic1I2Statement1BAJAJHCARE2026-09-30StatementDynamic1I3Statement1iso4217:INRxbrli:pureiso4217:INRxbrli:shares539872BAJAJHCARENOTLISTEDINE411U01027BAJAJ HEALTHCARE LIMITEDMain BoardEquity2026-04-012027-03-312026-10-172026-10-09INRLakhsQuarterlySecond quarterSingle segmentPharmaceuticals2026-10-1716:00:002026-10-1716:24:00trueCash Flow IndirectNot applicabletruetrueNANAfalsetrue2025-02-11 https://www.bajajhealth.com/policies/true1falseDuring the quarter ended 30th September 2026, there has been no default of any loan or debt securities.2026-07-012026-09-30UnauditedStandalone1759016000892400017679400009841210000-70396000191121000597530007649400034208800015831810001847590000184759000040961000409610000143798000-3819000-961000-28580000140940000224500014318500016832600054.274.26-0.08-0.084.194.180.482.264.091. The above financial results of Bajaj Healthcare Limited (the Company) have been reviewed by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on 17 October 2026. These results have been subjected to a limited review by the statutory auditors who have expressed an unmodified review conclusion. <br /> <br /> 2. The above un audited financial results for the quarter and half year ended 30 September 2026 have been prepared in accordance with the recognition and measurement principles laid down under Indian Accounting Standards (Ind AS), as prescribed under Section 133 of the Companies Act 2013 (Act) read with relevant rules issued thereunder and other accounting principles generally accepted in India in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. <br /> <br /> <br /> 3. The Company deals in pharmaceuticals products (formulations and active pharmaceutical ingredients components) which are interlinked and interdependent. Therefore, the Company has identified only one reportable segment i.e. Pharmaceuticals. <br /> <br /> <br /> 4. In the year ended 31 March 2024, the Board of Directors had approved to saledisposal of undertakingunit(s) on going concern basis, situated at plot no. N 92, L 93, T 30, MIDC Tarapur, Taluka Boisar, District Palghar, Maharashtra and vacant industrial land situated at plot no. D2CH42 and D2CH43 Dahej industrial area, GIDC, Bharuch, Gujarat (which were acquired under SARFAESI ACT, 2022 from Saraswat Bank) and plot no.E 62 and E 63 MIDC Tarapur, Taluka Boisar, District Palghar, Maharashtra. The approval of shareholders was obtained vide postal ballot. The Company has classified the assets and liabilities in relation to these units as Assets and liabilities held for saledisposal under Ind AS 105 (Non current Assets Held for Sale and Discontinued Operations). The results of the operation of these units have been presented separately on the Statement of Profit and Loss as Discontinued Operations. Out of these, one unit situated at plot no. N 92 was sold during the Quarter ended 31 March 2024 and L 93 was sold during the Quarter ended 31 March 2026. The Company has sold a portion of its Plot No. D 2CH42 and D 2CH43 Dahej Industrial Area, GIDC, Bharuch, Gujarat in the current quarter. The total value of assets classified as held for sale represents lower of carrying value or fair value. <br /> The financial information from discontinued operations: <br /> Particulars Quarter Ended Period ended Year ended <br /> 30 Sept 2026 30 June 2026 30 Sept 2025 30 Sept 2026 30 Sept 2025 31 March 2026 <br /> (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited) <br /> Total Income ( A ) 75.35 0.05 75.35 2.15 11.71 <br /> Total Expenses ( B ) 113.54 26.03 179.05 139.57 226.58 523.40 <br /> Loss before Tax from Discontinued Operations ( C = A B ) (38.19) (26.03) (179.00) (64.22) (224.43) (511.69) <br /> Tax Credit from Discontinued Operations ( D ) (9.61) (6.55) (45.06) (16.16) (56.49) 42.74 <br /> Loss after Tax from Discontinued Operations ( E = C D ) (28.58) (19.48) (133.94) (48.06) (167.94) (554.43) <br /> Subsequent to the quarter ended 30 September 2026, the Company has completed its sale of Plot No. D 2CH42 and D 2CH43 Dahej Industrial Area, GIDC, Bharuch, Gujarat. <br /> <br /> 5. On 23 June 2026, the Board of Directors of the Company approved the sale of its unit at Plot No. N 178, MIDC, Tarapur Industrial Area, Tarapur, Boisar, Palghar 401 506 with an unrelated party. The expected timeline for conclusion of Sale transaction is 31 October 2026. Hence, the unit has been classified as Property Held for Sale as at 30 September 2026. <br /> <br /> <br /> 6. During the financial year ended 31 March 2025, the Company allotted 39,84,852 equity shares and 20,79,409 convertible warrants on a preferential basis, raising an aggregate amount of Rs. 20,497.00 lakhs. The consideration for the equity shares was received in September 2024, and the shares were allotted in the same month. Further, 25 of the issue price of the convertible warrants was received in September 2024, and the balance 75 was received in March 2026. Subsequently, in March 2026, the Company approved the conversion of all 20,79,409 convertible warrants into an equivalent number of fully paid up equity shares of face value Rs. 5 each. <br /> The fund raised through allotment of equity shares and convertible warrants under the preferential issue has been utilised for following activities: Particulars Amount to be Utilised Utilised up to 30 Sept 2026 Unutilised Balance <br /> <br /> Repayment of loan 15,000.00 15,000.00 <br /> Investment in capital expenditure 3,500.00 2,912.48 587.52 <br /> General corporate purposes 1,997.00 1,993.48 3.52 <br /> Total 20,497.00 19,905.96 591.04 <br /> <br /> <br /> 7. In April 2025, the Company acquired Genrx Pharmaceuticals Private Limited (in Liquidation) (Genrx), an existing company incorporated under the provisions of the Companies Act, 1956, on a going concern basis for a total consideration of Rs.1,085.00 lakhs. <br /> Subsequently, on 3 June 2025, the Company filed an application before the Honble National Company Law Tribunal (NCLT), Mumbai Bench, seeking certain reliefs and concessions necessary for the effective implementation of the acquisition and takeover of Genrx as a going concern. The said application remained pending before the NCLT as on 30 September 2026. Accordingly, Genrx has not been considered a subsidiary of the Company for consolidation purposes, as control, as defined under Ind AS 110, Consolidated Financial Statements, had not been established as at the reporting date. <br /> However, on 13 October 2026, the Company received an order from the Honble NCLT approving the acquisition of Genrx on a going concern basis. <br /> Pursuant to the aforesaid order, Genrx Pharmaceuticals Private Limited will become a wholly owned subsidiary of Bajaj Healthcare Limited, subject to the implementation of the terms and conditions specified in the order passed by the Honble NCLT and the completion of the applicable procedural and legal formalities. 2026-04-012026-09-30UnauditedStandalone341533300017038000343237100019000120000-12532000036583300012066300014663200067520900030830290003493420000349342000066616000666160000282726000-6422000-1616000-48060000277920000449000028241000016831300058.48.38-0.14-0.148.268.240.482.493.9Debt Equity Ratio is 0.48DSCR is 2.49 for the half year ended 30 SEP 2026DSCR is 3.90 for the half year ended 30 SEP 2026Brokerage & Commission16220000Consumption of Stores Spares and Maintainence43469000Freight Forwarding & Transport27590000Legal & Professional Expenses22810000Material Testing & Inspection Charges13022000Power and Fuel79140000Processing & Labour Charges58182000Provision for Credit Loss25000000Repairs & Maintenance (Others)9494000Others47161000Brokerage & Commission26402000Consumption of Stores Spares and Maintainence110794000Freight Forwarding & Transport63446000Legal & Professional Expenses40326000Material Testing & Inspection Charges21443000Power and Fuel153947000Processing & Labour Charges116281000Provision for Credit Loss35000000Repairs & Maintenance (Others)14827000Others92743000228375300010664900000640290000002020000013234900013255100039991000740479000336745200023653400000251625300013473200074670000846370002743089000061439400057228230007212060000981148100016832600054032850005571611000557161100070380600000010945200081325800080785000000894043000197137100045256000106948500011147410001430140003229126000116380003222000003243986000101841000042398700009811481000Fixed deposits with remaining maturity more than 12 months23849000Amount paid for Investment in Genrx Pharma108500000Capital Advances418376000Non current tax Assets (Net)43991000Right of Use Assets278112000Advance to Staff4198000Deposits with original maturity of more than 12 months but maturing within 12 months from reporting date19661000Insurance Claim Receivable15235000Advance recoverable from related party - Genrx Pharma19150000Other Receivable26393000Balance with Statutory Authority369647000Deposit With Public Authorities and Others79594000Prepaid Expenses140965000Advance to Suppliers24188000Lease Liabilities109452000Nil0Employee related liability55729000Security Deposit received3000000Other Payables52289000Lease Liabillities31996000Statutory Dues Payable11638000120663000-205244000-2153590000-1072720000000-380580000964300000146632000350000000000-11875000016380009663000000-1601000000-1870680001622740000005407000015686700000000000756020006096250000000000000000000001638000052000-532333000001300000000450331000127038000205550005049800011440900000137844000-2376220000-237622000372354000134732000Remeasurement of defined benefit plans30000003000000Remeasurement of defined benefit plans6000000600000075500015100000022450004490000Bajaj Healthcare Limited******Mr. Sajankumar Rameshwarlal Bajaj******Chairman & Managing DirectorRemunerationNA2374800000Bajaj Healthcare Limited******Mr. Anil Champalal Jain******Managing DirectorRemunerationNA1999800000Bajaj Healthcare Limited******Ms. Namrata Sajankumar Bajaj******Whole-Time DirectorRemunerationNA269900000Bajaj Healthcare Limited******Mr. Pakshal Anil Jain******Whole-Time DirectorRemunerationNA270300000Bajaj Healthcare Limited******Mrs. Harshavi Pakshal Jain******Relative of DirectorRemuneration2000000Approved by the Audit Committee95600000Bajaj Healthcare Limited******Mrs. Khushi Jain******Relative of DirectorAny other transactionLegal & Professional Fees1200000Approved by the Audit Committee3600001800000Bajaj Healthcare Limited******Mrs. Nihita Bajaj Kumar******Relative of DirectorAny other transactionLegal & Professional Fees2400000Approved by the Audit Committee120000000Bajaj Healthcare Limited******Taradevi Rameshwarlal Bajaj Charitable Trust******Charitable TrustAny other transactionCSR Expenses10000000Approved by the Audit Committee03300033000Bajaj Healthcare Limited******Genrx Pharmaceuticals Private Limited******Body corporate directly/ indirectly owned by or significantly influenced by Director/s or their relativesAny other transactionOperating Expenses incurred by Bajaj on behalf of Genrx Pharmaceuticals50000000Approved by the Audit Committee87880001036200019150000Bajaj Healthcare Limited******Bajaj Sindhudurg Rice Mills Limited******Body corporate directly/ indirectly owned by or significantly influenced by Director/s or their relativesAny other transactionRepayment of Advance10000000Approved by the Audit Committee1000000185200085200061452000OthersAllotment of Equity Shares pursuant to the exercise of options for conversion of convertible warrants into equity shares2026-03-185271300002026-09-30trueCARE Ratings LimitedfalseNot ApplicableNo CommentsNo CommentsRohan ParekhChief Financial OfficerThane2026-10-17Repayment & Prepayment of Secured/Unsecured Loans from Bank/NBFC in part or in fullNot Applicable1500000000150000000015000000000Investment in Capital ExpenditureNot Applicable3500000003500000002912480000General Corporate PurposeNot Applicable2200000001997000001993480000